Browse every story filed under this topic, curated from trusted publishers around the world.
Novartis rounds out $23B US investment push with plans for North Carolina API plant
Novartis will construct an active pharmaceutical ingredient (API) facility in Morrisville, North Carolina, the company said Thursday. The 56,200 square-foot plant will manufacture compounds for solid dose tablets, capsules and RNA therapeutics.
Read full story →
First patient dosed in Newleos’ Phase Ib trial of NTX-2001
Newleos Therapeutics has dosed the first participant in its Phase Ib clinical study evaluating NTX-2001, a partial agonist of TAAR1, …
Ray Therapeutics receives EMA PRIME status for gene therapy
Ray Therapeutics has received PRIME designation from the EMA for its RTx-015 gene therapy to treat retinitis pigmentosa (RP).
Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
Partnership to support selection of first neoantigen therapy candidate
Compass Therapeutics’s stock crashes after OS miss in BTC trial
Compass Therapeutics will still submit tovecimig for approval despite the OS miss in BTC. The post Compass Therapeutics’s stock crashes …
BioMarin acquires Amicus Therapeutics for $4.8bn
BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal.
Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
Lead asset shows systemic, dose‑dependent anti‑tumour activity
Oruka reports positive data from Phase IIa trial for plaque psoriasis
Oruka Therapeutics has reported positive interim data from the ongoing EVERLAST-A Phase IIa trial evaluating ORKA-001 in patients with moderate-to-severe …
Intellia’s Data Reveal Tees Up FDA Filing for CRISPR-Based In Vivo Gene-Editing Med
Intellia Therapeutics’ lonvo-z uses CRISPR to inactivate a gene in the liver to reduce levels of a protein key to …
Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics
Ajax’s lead asset is AJ1-11095, a once-daily Type II JAK2 inhibitor taken orally, which is currently in a Phase I …
STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study
A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical trial, its …
VC Firm Kurma Partners Closes €215M Fund in Pursuit of ‘Disruptive Therapeutic Solutions’
Kurma Partners’ new fund is the venture capital firm’s fourth and largest. Previous Kurma investments have led to exits that …
FDA snubs AbbVie's prospective Botox heir amid series of manufacturing-related CRLs
The FDA rejected two new products from AbbVie and Grace Therapeutics, citing manufacturing-related concerns.
Travere’s launchpad positions Filspari for fast rise toward blockbuster sales: analyst
An established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its new …
Fierce Pharma Asia—Merck’s PD-1xVEGF data; Zai Lab’s global view; Kailera’s record IPO
Merck & Co. unveiled the much-anticipated first look at its PD-1xVEGF bispecific data. China's Zai Lab is looking to go …
ESCMID Global 2026: Zelicapavir demonstrates benefits for high-risk adults with RSV
Enanta is in a strong position to dominate the largely untapped RSV therapeutics market with a Phase III trial on …
ModeX starts dosing in MDX2003 trial for B-cell lymphoma
ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for relapsed or refractory B-cell lymphoma. The post …
BioAegis and Prenosis partner for inflammatory disease therapies
BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases.
STAT+: Kyverna Therapeutics plans to submit cell therapy for stiff person syndrome for FDA approval
A one-time cell therapy from Kyverna Therapeutics for stiff person syndrome, a rare disease, improved mobility and reduced disabilities in …
Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain
Tortugas Neurosciences’ two lead programs are in-licensed oral small molecules in development for schizophrenia and tinnitus. The startup is led …
You've seen all articles for #therapeutics.
Check back
soon
for new stories.